title: Abiraterone and novel antiandrogens: overcoming castration resistance in prostate cancer.
abstract: Suppression of gonadal androgens by medical or surgical castration remains the mainstay of treatment for patients with advanced prostate cancer. However, the response to treatment is not durable, and transition to a "castration-resistant" state is invariable. Recent advances in our understanding of the androgen receptor signaling pathway have led to the development of therapeutic strategies to overcome castration resistance. This article reviews current concepts and challenges behind targeting continued androgen receptor signaling in castration-resistant prostate cancer and provides an overview of recently completed and ongoing clinical trials of novel hormonal agents, with a focus on abiraterone acetate and enzalutamide (MDV3100).
authors.affiliation: Division of Cancer Therapeutics, Signal Transduction & Molecular Pharmacology and Clinical Pharmacology & Trials Team, Institute of Cancer Research, Sutton, SM25NG, United Kingdom. Roberta.ferraldeschi@icr.ac.uk
authors.forename: R
authors.initials: R
authors.lastname: Ferraldeschi
authors.forename: C
authors.initials: C
authors.lastname: Pezaro
authors.forename: V
authors.initials: V
authors.lastname: Karavasilis
authors.forename: J
authors.initials: J
authors.lastname: de Bono
mesh_terms: D000726:Androgen Antagonists / Q000627:therapeutic use*; D000728:Androgens / Q000378:metabolism*; D000736:Androstenes; D000737:Androstenols / Q000627:therapeutic use*; D002369:Castration; D006801:Humans; D008297:Male; D011471:Prostatic Neoplasms / Q000378:metabolism / Q000628:therapy*; D016896:Treatment Outcome
chemical_list: D000726:Androgen Antagonists; D000728:Androgens; D000736:Androstenes; D000737:Androstenols; C089740:abiraterone